Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models.

The median survivals of the control group and the 2 groups treated with 100 and 300 μg/kg of SGN CD70A were 20 days, 28 days, and 57 days, respectively; and the survival difference between the SGN-CD70A 300 and the control group was highly significant, with P = .0069 ( Figure 4B ).

also in 132,142 other papers